XM does not provide services to residents of the United States of America.
L
L

Lonza


News

Lonza And Vertex Sign A Supply Agreement For Casgevy®

BRIEF-Lonza And Vertex Sign A Supply Agreement For Casgevy® Sept 24 (Reuters) - LONZA GROUP AG LONN.S : LONZA AND VERTEX SIGN A LONG-TERM COMMERCIAL SUPPLY AGREEMENT FOR CASGEVY® (EXAGAMGLOGENE AUTOTEMCEL) LONZA GROUP AG - TO MANUFACTURE WORLD'S FIRST CRISPR/CAS9 CELL THERAPY LONZA GROUP AG - GELEEN (NL) SITE IS NOW APPROVED BY FDA, EMA AND MHRA
L

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2

BUZZ-Stifel adjusts ratings on European pharma; downgrades Sartorius, Siegfried ahead of H2 ** Stifel shares thoughts on European pharmaceutical companies heading into H2; downgrades Sartorius SATG.DE and Siegfried SFZN.S to "hold", citing concerns over growth catalysts and valuation alignment with recent strong performance ** The analyst flags the
L

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U

Swiss stocks - Factors to watch on September 13

Swiss stocks - Factors to watch on September 13 ZURICH/GDANSK, Sept 13 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Friday: A survey of Swiss banks has highlighted international sanctions imposed on other countries, such as against Russia over Ukraine, as the greatest geopolitical risk to their business. ANALYSTS' VIEWS ABB ABBN.S - HSBC RAISES TARGET PRICE TO CHF 45 FROM CHF 43 ALCON ALCC.S - HSBC CUTS TARGET PRICE TO CHF 89 FROM CHF 91 LONZA LONN.S - HSBC RAISE
A
L
S
S

Swiss stocks - Factors to watch on August 29

Swiss stocks - Factors to watch on August 29 ZURICH/GDANSK, Aug 29(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: Swiss court convicts two executives over $1.8 billion 1MDB fraud The Swiss Federal Criminal Court convicted on Wednesday two executives at an oil exploration company for embezzling more than $1.8 billion from Malaysia's state investment fund 1MDB.
L
S

Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds

BRIEF-Lonza Says Co Prices EUR 1.2 Bln Dual-Tranche Straight Bonds Aug 28 (Reuters) - Lonza Group AG LONN.S : LONZA PRICES EUR 1.2 BILLION DUAL-TRANCHE STRAIGHT BONDS LONZA GROUP - BONDS FOR LONZA FINANCE INTERNATIONAL HAVE MATURITY OF 6 AND 10 YEARS WITH COUPONS OF 3.25% AND 3.50% RESPECTIVELY Source text for Eikon: ID:nEQbznFm8a Further company c
L

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

Swiss stocks - Factors to watch on July 26

Swiss stocks - Factors to watch on July 26 July 26 - Here are some of the main factors that may affect Swiss stocks on Friday: HOLCIM HOLN.S Reports Q2 results slightly ahead of forecasts. COMPANY STATEMENTS AMS OSRAM AMS.S Second quarter earnings release due. FORBO HOLDING FORN.S Confirms spring outlook for full year 2024. VONTOBEL VONN.S Half-year earnings release due.
A
L
N
S
J

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

Swiss pharma firm Lonza hits 1-year high on earnings beat

BUZZ-Swiss pharma firm Lonza hits 1-year high on earnings beat Updates share move, adds milestone ** Shares in Lonza LONN.S jump 8% to their highest level in a year after the Swiss contract drug manufacturer's H1 core earnings fell less than expected by the market ** The stock tops the broad Swiss blue-chip index .SSMI , which was down 0.5% by 0717
L
S

Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop

BUZZ-Swiss pharma firm Lonza seen up on smaller-than-expected earnings drop ** Shares in Swiss contract drug manufacturer Lonza LONN.S are seen rising 3.5% in the Julius Baer premarket indications after its H1 core earnings fell less than expected by the market ** H1 adjusted EBITDA fell to 893 million Swiss francs ($976.4 million), vs 802 million
L
J

Swiss pharma firm Lonza's profit falls less than feared, shares rise

UPDATE 3-Swiss pharma firm Lonza's profit falls less than feared, shares rise Rewrites with details on shares, adds analyst comment, details on Biologics unit, background; paragraphs 1-4 By Isabel Demetz and Andrey Sychev July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a smaller-than-expected decline in first-half profit on Thursday, as a strong performance in its core Biologics unit partly offset weak demand for capsules.
C
L
S

Swiss pharma supplier Lonza reports lower half-year results

Swiss pharma supplier Lonza reports lower half-year results July 25 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S reported a drop in its half year profit, hurt by lacklustre demand in its capsules and health ingredients businesses, but beat market estimates, it said on Thursday. It reported an adjusted core earnings before interest, taxes, depreciation and amortization (EBITDA) of 893 million Swiss francs ($976.4 million), compared to 922 million Swiss francs a year earlier.
L

Swiss stocks - Factors to watch on July 25

Swiss stocks - Factors to watch on July 25 ZURICH/GDANSK, July 25(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS DORMAKABA DOKA.S Dormakaba expands production in India. LEONTEQ LEON.S Leonteq says outlook for 2024 is reaffirmed. BUCHER INDUSTRIES AG BUCN.S Bucher Industries says group expects lower sales in 2024. BACHEM HOLDING AG BANB.S Half-year results due.
L
N
R
S
J
S



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.